Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) (SYNPHENY-3)
A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Sponsor: Synlogic
Terminated
Based on a review of interim data from participants in the dose-escalation phase, it was determined that the study was unlikely to meet the primary endpoint.
Other terminated trials from Synlogic
More terminations from Synlogic
This PHASE3 trial investigates Phenylketonuria and is currently terminated or withdrawn. Synlogic leads this study, which shows 14 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
-
Mar 2024 — Apr 2024 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
▶ Show 9 earlier versions
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Synlogic
For direct contact, visit the study record on ClinicalTrials.gov .